MPM Capital has closed an oversubscribed $400m life sciences venture fund that counts Novartis and Astellas among its limited partners.

Dimension Therapeutics, a life sciences startup partnered with Pennsylvania University, raises $65m in series B.

Medtech startup Color Genomics secures $15m series A for genetic testing kits.

Qura Therapeutics will develop HIV treatments in partnership with University of North Carolina at Chapel Hill, a venture in which it is investing $20m.

Existing investor SoftBank returned to back a $9.5m funding round for the on-demand therapist service, which has now raised $13m in the past year.

Green Cross and Posco Capital co-led a $7.5m series B-2 round for the Takeda-backed regenerative medicine developer, which has now raised almost $40m in total.

The partnership, formed to develop immuno-oncology drugs, will include a $30m equity investment in BioNTech subsidiary Cell & Gene Therapies.

Pfizer also picked up the right to acquire AbbVie-backed AM-Pharma, the developer of a treatment for acute kidney disease, in a deal that could eventually total $600m.

Two Oregon University spin-outs snap up $110,000 in backing from state-backed economic development office Business Oregon.

Catholic University of Louvain communications spin-out Tessares secures backing from telecoms firm Proximus and university investor Louvain Technology Fund.